Allspring Global Investments Holdings LLC Buys 1,045,305 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Allspring Global Investments Holdings LLC raised its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2,018.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 1,097,096 shares of the company’s stock after purchasing an additional 1,045,305 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.10% of Teva Pharmaceutical Industries worth $23,368,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in TEVA. Creative Planning raised its holdings in Teva Pharmaceutical Industries by 4.5% in the 3rd quarter. Creative Planning now owns 42,815 shares of the company’s stock valued at $772,000 after acquiring an additional 1,863 shares in the last quarter. Claro Advisors LLC bought a new position in Teva Pharmaceutical Industries in the third quarter worth $52,000. Blue Trust Inc. boosted its stake in Teva Pharmaceutical Industries by 40.1% during the third quarter. Blue Trust Inc. now owns 14,619 shares of the company’s stock worth $263,000 after buying an additional 4,185 shares in the last quarter. Raymond James & Associates increased its holdings in Teva Pharmaceutical Industries by 25.1% in the 3rd quarter. Raymond James & Associates now owns 1,020,719 shares of the company’s stock valued at $18,393,000 after buying an additional 204,775 shares during the period. Finally, Sequoia Financial Advisors LLC raised its stake in shares of Teva Pharmaceutical Industries by 0.7% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock valued at $2,025,000 after buying an additional 805 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Wall Street Analysts Forecast Growth

TEVA has been the topic of a number of analyst reports. UBS Group lowered their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. StockNews.com cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Barclays decreased their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. JPMorgan Chase & Co. increased their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. Finally, Piper Sandler boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $23.57.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the sale, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Roberto Mignone sold 286,000 shares of the firm’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the transaction, the director now directly owns 695,000 shares in the company, valued at $15,296,950. This trade represents a 29.15 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock opened at $16.24 on Friday. The stock has a 50-day simple moving average of $19.96 and a 200 day simple moving average of $18.50. The stock has a market capitalization of $18.39 billion, a price-to-earnings ratio of -11.20, a P/E/G ratio of 1.39 and a beta of 0.71. The company has a quick ratio of 0.61, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 12-month low of $12.51 and a 12-month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.62 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.